These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16764996)

  • 41. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of benign prostatic hyperplasia disease.
    Marks LS; Roehrborn CG; Andriole GL
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
    Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
    BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.
    O'Leary MP; Wei JT; Roehrborn CG; Miner M;
    BJU Int; 2008 Jun; 101(12):1531-5. PubMed ID: 18445080
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effects of transurethral catheterization on uroflow rate in the pressure-flow study of patients with benign prostatic hyperplasia].
    Zhao SC; Zheng SB; Tan WL; Mao XM; Zhang P; Huang ZM; Zhang HJ; Zuo Y
    Zhonghua Nan Ke Xue; 2007 Aug; 13(8):710-2. PubMed ID: 17918710
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
    Zhigang Z; Wenlu S
    Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased expression of NKX3.1 in benign prostatic hyperplasia.
    Irer B; Toylu A; Aslan G; Celebi I; Yorukoglu K; Atabey N
    Urology; 2009 May; 73(5):1140-4. PubMed ID: 18597829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Graphic interpretation of pressure-flow analysis].
    Boiteux JP
    Prog Urol; 1998 Dec; 8(6):1065-73. PubMed ID: 9894271
    [No Abstract]   [Full Text] [Related]  

  • 53. Assessment of prostatic obstruction: A cuff may be enough.
    Drinnan MJ; Pickard RS; Ramsden PD; Griffiths CJ
    Neurourol Urodyn; 2003; 22(1):40-4. PubMed ID: 12478600
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.
    Ikuerowo SO; Akindiji YO; Akinoso OA; Akinlusi FM; Esho JO
    Urol Int; 2008; 80(3):296-9. PubMed ID: 18480635
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The autonomic nervous system function in benign prostatic hyperplasia].
    Thor PJ; Mazur M; Furgała A; Worek M
    Folia Med Cracov; 2006; 47(1-4):79-86. PubMed ID: 18038615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Catheter-free 120W lithium triborate (LBO) laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH).
    Spaliviero M; Araki M; Page JB; Wong C
    Lasers Surg Med; 2008 Oct; 40(8):529-34. PubMed ID: 18798292
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlations between urethral elastance and histological architecture in patients with benign prostatic hyperplasia.
    Ichiyanagi O; Sasagawa I; Aoyama N; Ishigooka M; Kubota Y; Nakada T
    Scand J Urol Nephrol; 1998 May; 32(3):215-8. PubMed ID: 9689702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of retrospective quality control on pressure-flow data with computer-based urodynamic systems from men with benign prostatic hyperplasia.
    Liao LM; Schaefer W
    Asian J Androl; 2007 Nov; 9(6):771-80. PubMed ID: 17968462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.